Last reviewed · How we verify
NCT05668078
Effectiveness of Rapid Antigen Testing of Students for COVID-19 in Reducing Absences From Schools in Bangladesh
NA trial testing Rapid Antigen Testing (RAT) for COVID-19 in School Absenteeism in 1,141 participants. Completed in 30 July 2022.
30 July 2022
Quick facts
| Lead sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 1,141 |
| Start date | 18 May 2022 |
| Primary completion | 30 July 2022 |
| Estimated completion | 30 July 2022 |
| Sites | 1 location across Bangladesh |
Drugs / interventions tested
- Rapid Antigen Testing (RAT) for COVID-19
Conditions studied
- School Absenteeism — all drugs for School Absenteeism →
Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh — full company profile →
Who can join
Adults 13 to 19, any sex, with School Absenteeism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this trial is to evaluate the impact of different testing strategies with Rapid Antigen Testing (RAT) on reduction of school absences. RATs are relatively inexpensive, fast, and can be performed at the point of care. Provision of testing in schools will allow rapid identification and isolation of individuals infected with Covid-19. This will likely reduce COVID-19 transmission, as well as allow symptomatic COVID-19 negative students to return to classroom, avoiding the 10-days isolation period. If proven successful, the lessons from this study can be translated to schools in similar settings. While several testing strategies have been proposed and evaluated in developed countries, no studies have evaluated the role of testing for safe operation of schools or reducing absenteeism in developing country contexts.The lessons learned from this study is likely to inform government policy regarding the provision of testing in school. Study design: Cluster randomized trial School types: Three types based on testing: * Intervention school-1: Test all symptomatic students, teachers, and support staff ; and track symptoms and absenteeism * Intervention school-2: Test all students, teachers, and support staff every 3 days, irrespective of symptoms (also test whenever develops symptoms) and track symptoms and absenteeism * Control school: Only track the students for symptom notification and absenteeism
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05668078
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other International Centre for Diarrhoeal Disease Research, Bangladesh trials
Trials by the same sponsor.
- NCT07537686 — Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunc · Phase 2 · not yet recruiting
- NCT07345208 — Safety and Immunogenicity of ID vs IM Rabies Vaccine · Phase 2, PHASE3 · not yet recruiting
- NCT07045493 — Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in Bangladesh · Phase 2 · enrolling by invitation
- NCT06757283 — ZyVac-TCV Bangladesh Study · Phase 3 · not yet recruiting
- NCT06815835 — Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05668078 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International Centre for Diarrhoeal Disease Research, Bangladesh
- Last refreshed: 29 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05668078.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing